AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Christoph Hiemke1, Pierre Baumann2, N. Bergemann3, Andreas Conca3, Otto Dietmaier3, Karin Egberts4, Mirijam Fric5, M. Gerlach4, C. Greiner6, Gerhard Gründer1, Ekkehard Haen7, Ursula Havemann‐Reinecke8, E Jaquenoud Sirot3, Hartmut Kirchherr9, Gerd Laux5, Ulrich Lutz1, Thomas Messer3, Markus Müller3, Bruno Pfuhlmann10, B. Rambeck11, Peter Riederer10, Bernd Schoppek3, Julia C. Stingl12, Manfred Uhr13, S. Ulrich14, R. Waschgler3, Gerald Zernig1
1Department of Psychiatry and Psychotherapy
2Department of Psychiatry, University of Lausanne
3Psychiatric Hospital
4Department Child and Adolescent Psychiatry
5Kliniken des Bezirks Oberbayern (kbo) Salzach-Inn-Klinikum
6Federal Institute for Drugs and Medical Devices (BfArM)
7Clinical Pharmacology, Department of Psychiatry and Psychosomatics
8Department of Psychiatry and Psychosomatics
9Medical Laboratory Bremen
10Department of Psychiatry, Psychotherapy and Psychosomatics
11Center of Epilepsy
12Department of Pharmacology of Natural Products and Clinical Pharmacology
13Max Planck Institute of Psychiatry
14Aristo Pharma GmbH
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Pharmacopsychiatry
Tập 44 Số 06
195-235
Thông tin tác giả